Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of primary tumor and conformed brain metastases by enhanced MRI or CT~* the lesion number is no less than 3; or the tumor volume is no smaller than 6cc; or tumor diameter is no shorter than 3cm; or uncontrolled brain tumor after whole brain radiotherapy(WBRT); or the tumor is adjacent to essential structures of the brain, such as brain stem, optic chiasma, optic tract, etc.~* KPS ≥60，or KPS ≥40 and the limitation of motion is simply caused by brain tumor that is adjacent to the motor function areas.~* Age: 18-75 years old.~* Adequate end-organ function:~WBC≥4.0x109/L Neu ≥ 1.5x109/L Hemoglobin ≥ 110 g/L Platelets ≥100 x109/L Total bilirubin ≤ 1.5x ULN AST and ALT ≤ 1.5x ULN BUN and Cr: within the normal range~Exclusion Criteria:~* Other clinically significant diseases (e.g.myocardial infarction within the past 6 months, severe arrhythmia).~* Unable or unwilling to comply with the study protocol.~* The expected survival time is less than 3 months.~* Patients who are anticipated in other clinical trials of brain metastases.~* Patients who has been treated with SRT in other hospitals~* Pregnant patients or female patients whose HCG is positive~* Unsuitable to participate in study, that in the opinion of the treating physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Refractory Brain Metastases (Type: EXPERIMENTAL): Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases

Based on this trial design, predict the completion outcome and termination type (if applicable).